Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Good Nuedexta Trends Continues, Phase 2 Progress
AVNR Hot Sheet
Rating Summary:2 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta’s steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudo-bulbar affect, emotional lability seen in stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Phase 2 MS Pain PRIME trial well underway; PBA prevalence data from PRISM registry expected in 2012. We expect PRISM and PRIME data (H2/13) to be sales and stock drivers."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $3.17 yesterday, with a 52 week range of $1.77-$4.80.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta’s steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudo-bulbar affect, emotional lability seen in stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Phase 2 MS Pain PRIME trial well underway; PBA prevalence data from PRISM registry expected in 2012. We expect PRISM and PRIME data (H2/13) to be sales and stock drivers."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $3.17 yesterday, with a 52 week range of $1.77-$4.80.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
- Oppenheimer Reiterates an 'Outperform' on MakeMyTrip (MMYT); Updating Estimates Ahead of March Qtr
- Nomura Securities Maintains a 'Neutral' on Yahoo! (YHOO); Monetizing Alibaba
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
